Abstracts tagged "Clinical practice"

Abstract Number: 1555 • 2017 ACR/ARHP Annual Meeting
Treatment Changes By Joint Activity and Skin Severity in Patients with Comorbid Psa and Pso
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Treatment of both joint and skin symptoms is important for overall disease management of patients with psoriatic arthritis and comorbid psoriasis1,2. The objective of…
Abstract Number: 607 • 2017 ACR/ARHP Annual Meeting
Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials
Philip J Mease¹, Mark Lebwohl², Isabelle Gilloteau³, Todd Fox³, Jaime Oliver³, Steffen Jugl³ and Alice B Gottlieb⁴, ¹University of Washington School of Medicine and Swedish Medical Center, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Novartis Pharma AG, Basel, Switzerland, ⁴Department of Dermatology, New York Medical College, Vallhalla, NY
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody selectively neutralizing interleukin-17A, exhibits significant efficacy, with a favorable safety profile, in the treatment of psoriatic arthritis…
Abstract Number: 1559 • 2017 ACR/ARHP Annual Meeting
Residual Disease Activity in Psoriatic Arthritis Triggers Treatment Adjustment in Only a Quarter of Patients in Daily Clinical Practice
Leonieke van Mens¹, Sadaf Atiqi², Inka Fluri², Marleen van de Sande³, Arno van Kuijk⁴ and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: With expanding therapeutic possibilities for the treatment of psoriatic arthritis (PsA) it will be increasingly important to determine residual disease and define when to…
Abstract Number: 743 • 2017 ACR/ARHP Annual Meeting
Impact of Detect on Right Heart Catheterization Referral and Results; Data from a Prospective, Unselected, Systemic Sclerosis Cohort
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim², Anders Heiervang Tennøe², Oyvind Midtvedt², Torhild Garen², Einar Gude², Arne K Andreassen² and Øyvind Molberg², ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway
Background/Purpose: The DETECT calculator has been freely available as a tool for earlier detection and diagnosis of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)…
Abstract Number: 1690 • 2017 ACR/ARHP Annual Meeting
Nailfold Capillary Counts Are Associated with Clinical Manifestations in Connective Tissue Disease Japanese Patitents
Atsushi Kondo¹, Tomohiro Kameda¹, Miharu Izumikawa¹, Hiromi Shimada², Shusaku Nakashima¹, Risa Wakiya¹, Mikiya Kato¹, Norimitsu Kadowaki¹ and Hiroaki Dobashi¹, ¹Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, ²Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: Connective tissue diseases (CTD) patients have various clinical manifestation including pulmonary hypertension (PH) and digital ulcer (DU). Especially, Raynaud’s phenomenon (RP) is one of…
Abstract Number: 816 • 2017 ACR/ARHP Annual Meeting
Comparison between Giacta Trial and a Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice with Tocilizumab
Nuria Vegas-Revenga¹, Javier Loricera¹, Antonio Mera², Eva Pérez- Pampín², Santos Castañeda³, Lucia C. Domínguez-Casas¹, José Luis Martín-Varillas⁴, Belén Atienza-Mateo⁴, MC Gonzalez-Vela¹, Jose L. Hernández⁵, Miguel Angel González-Gay⁴ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Complejo Hospitalario Universitario de Santiago. Galicia. Spain, Santiago de Compostela, Spain, ³Hospital Universitario de La Princesa, Madrid. Spain, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁵Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: GiACTA study is a randomized, phase III controlled clinical trial of tocilizumab (TCZ) in giant cell arteritis (GCA) (1,2). Our aim was to compare…
Abstract Number: 2059 • 2017 ACR/ARHP Annual Meeting
Allopurinol Dose-Titration Patterns Relative to Serum Uric Acid Levels in Gout Patients: US Electronic Health Record Data
An-Chen Fu, Douglas C.A. Taylor and David S. Reasner, Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Allopurinol is a first-line urate-lowering therapy…
Abstract Number: 1046 • 2017 ACR/ARHP Annual Meeting
Biological and Targeted Synthetic Dmards’ Prior Authorization Time Is Significantly Reduced with Pharmacy Presence in the Rheumatology Clinic
Wendy Ramey¹, Kristine M. Lohr², Matt Zeltner¹, Haley Herrell Postonl¹, Andrew Johannemann¹, Aric D. Schadler¹ and Aleksander Lenert³, ¹University of Kentucky, Lexington, KY, ²Rheumatology, University of Kentucky, Lexington, KY, ³Internal Medicine, Div. of Rheumatology, University of Kentucky, Lexington, KY
Background/Purpose: Treatment with biological DMARDs (bDMARD) and targeted synthetic DMARDs (tsDMARD) has led to improved outcomes for chronic rheumatic diseases. Current treat-to-target (T2T) strategy relies…
Abstract Number: 2452 • 2017 ACR/ARHP Annual Meeting
In Real-World Clinical Practice, Patients Switching from IV to SC Abatacept Maintain Clinical Efficacy after Switch
Rieke Alten¹, HM Lorenz², X Mariette³, H Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, J Heitzmann⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen-Nuremberg, Nuremberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: Patients (pts) with RA may be able to switch from IV to SC abatacept with no loss of efficacy or safety concerns, but data…
Abstract Number: 114 • 2017 Pediatric Rheumatology Symposium
Clinical Features and Treatment Outcomes in Down’s Arthropathy
Jordan T. Jones¹ and Leena Danawala², ¹Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, ²University of Missouri-Kansas City School of Medicine, Kansas City, MO
Background/Purpose: Crude prevalence estimates indicate Down’s Arthropathy (DA) is 3-8 times more common than juvenile idiopathic arthritis (JIA), however, DA is still largely under recognized…
Abstract Number: 2213 • 2016 ACR/ARHP Annual Meeting
The Four Stages of Fibromyalgia: Potential for More Precise Treatment Approaches
Mark Gostine¹, Fred Davis¹, Bradley Roberts², Rebecca Risko², Joseph C Cappelleri³, Andrew Clair⁴ and Alesia Sadosky⁵, ¹Michigan Pain Consultants, PC, Grand Rapids, MI, ²ProCare Systems, Inc., Grand Rapids, MI, ³Statistics, Pfizer Inc, New London, CT, ⁴Pfizer, New York, NY, ⁵Pfizer Inc,, New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and tenderness making it difficult to manage. Accounting for FM heterogeneity might elicit an improvement in…
Abstract Number: 2318 • 2016 ACR/ARHP Annual Meeting
Real World Use of the Myositis Autoantibody Panel
Jason Weiner¹, Ryan Jessee², Robert T. Keenan³, Michael Datto⁴ and Lisa Criscione-Schreiber⁵, ¹Division of Rheumatology, Duke University, Durham, NC, ²Division of Internal Medicine, Duke University, Durham, NC, ³Rheumatology, Duke University, Durham, NC, ⁴Division of Pathology, Duke University, Durham, NC, ⁵Division of Rheumatology, Department of Medicine, Duke University, Durham, NC
Background/Purpose: The identification of myositis specific and associated autoantibodies occurring in idiopathic inflammatory myopathies (IIMs) has improved classification and prognosis determinations. With commercial availability, these…
Abstract Number: 2658 • 2016 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Dalifer Freites Núñez¹, Cynthia Milagros León Cárdenas¹, Cristina Lajas Petisco¹, Leticia Leon², Luis Rodriguez Rodriguez², Juan A Jover Jover¹ and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a high risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 2686 • 2016 ACR/ARHP Annual Meeting
Objective Improvement in Fatigue Scores for Primary Sjögren’s Patients Receiving a Tailored Multidisciplinary Fatigue Intervention in a Generic Fatigue Clinic
Katie Hackett^1,2, Robert Forder³, Dennis W Lendrem⁴, Ben Hargreaves⁵, Victoria Strassheim^1,3, Zoe Gotts³, Vincent Deary^1,6, Wan-Fai Ng^7,8 and Julia Newton^1,3, ¹CRESTA Fatigue Clinic, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵Musculoskeletal Directorate, Newcastle upon Tyne NHS Foundation Trust, Newcastle, United Kingdom, ⁶School of Health Psychology, Northumbia University, Newcastle upon Tyne, United Kingdom, ⁷Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle University, Newcastle, England, ⁸Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (PSS) is an autoimmune disease which targets secretary glands resulting in dry eyes and mouth. Approximately 70% of PSS patients experience…
Abstract Number: 81 • 2016 ACR/ARHP Annual Meeting
Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey
Ara Dikranian¹, James Galloway², Joern Kekow³, Cristiano A.F Zerbini⁴, Maria de la Vega⁵, Gavin Lee⁶, Anna Maniccia⁷, Eustratios Bananis⁸, Dario Ponce de Leon⁹ and Allan Gibofsky¹⁰, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²King's College, and King´s College Hospital, London, United Kingdom, ³University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany, ⁴Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁵CEIM Investigaciones Médicas, Buenos Aires, Argentina, ⁶Hong Kong Sanatorium & Hospital, Hong Kong SAR, China, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Inc, Lima, Peru, ¹⁰Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY
Background/Purpose: RA is a chronic, debilitating condition for which there is no cure. To identify and better understand the perspectives of both healthcare providers (HCPs)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.